Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo by Bekkering, S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/165679
 
 
 
Please be advised that this information was generated on 2019-06-01 and may be subject to
change.
Innate immune cell activation and epigenetic remodeling in
symptomatic and asymptomatic atherosclerosis in humans in vivo
Siroon Bekkering a, 1, Inge van den Munckhof a, Tim Nielen b, Evert Lamfers b,
Charles Dinarello a, c, Joost Rutten a, Jacqueline de Graaf a, Leo A.B. Joosten a,
Mihai G. Netea a, Marc E.R. Gomes b, Niels P. Riksen a, *
a Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
b Department of Cardiology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
c University of Colorado Denver, Aurora, CO 80045, USA
a r t i c l e i n f o
Article history:
Received 9 July 2016
Received in revised form
29 September 2016
Accepted 11 October 2016
Available online 12 October 2016
Keywords:
Atherosclerosis
Monocytes
Inﬂammation
Metabolism
Epigenetics
a b s t r a c t
Background and aims: We have recently reported that monocytes can undergo functional and tran-
scriptional reprogramming towards a long-term pro-inﬂammatory phenotype after brief in vitro expo-
sure to atherogenic stimuli such as oxidized LDL. This process is termed ‘trained immunity’, and is
mediated by epigenetic remodeling and a metabolic switch towards increased aerobic glycolysis. We
hypothesize that trained immunity contributes to atherogenesis. Therefore, we investigated the in-
ﬂammatory phenotype and epigenetic remodeling of monocytes from patients with and without
established atherosclerosis.
Methods: Monocytes were isolated from 20 patients with severe symptomatic coronary atherosclerosis
(total plaque score >4 on coronary computed tomography angiography) and 17 patients with asymp-
tomatic carotid atherosclerosis and matched controls for both groups. Ex vivo stimulation, RNA analysis
and chromatin immunoprecipitation were performed.
Results: Monocytes from patients with symptomatic atherosclerosis have a higher production of pro-
inﬂammatory cytokines upon LPS stimulation than healthy controls (TNFa 499 ± 102 vs. 267 ± 45 pg/
ml, p ¼ 0.01). This was associated with lower histone 3 lysine 4 trimethylation (H3K4me3) (19% vs. 33%,
p ¼ 0.002), and lower H3K27me3 (0.005% vs. 0.8%, p < 0.0001) on the TNFa promoter. Furthermore,
relative mRNA expression of the glycolytic rate limiting enzymes hexokinase 2 and 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 3 was higher in patients (0.7 ± 0.2 vs. 0.3 ± 0.1 resp. 1.7 ± 0.2 vs.
1.0 ± 0.1, p ¼ 0.007 resp. 0.003) compared to control individuals. Interestingly, this pro-inﬂammatory
phenotype was only present in patients with symptomatic atherosclerosis, and not in patients with
asymptomatic carotid atherosclerosis.
Conclusions: Circulating monocytes of patients with symptomatic, but not asymptomatic, atherosclerosis
have a pro-inﬂammatory phenotype and increased expression of glycolytic enzymes, associated with
epigenetic remodeling at the level of histone methylation.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Cardiovascular diseases (CVD) are the leading cause of death
worldwide, projected to cause 30 million deaths per year in 2030
[1]. The main underlying pathological process of CVD is athero-
sclerosis, a chronic low-grade inﬂammatory disorder of the arterial
wall. Macrophages are the most abundant cells found in plaques
and play central roles in the various stages of atherosclerosis [2].
Plaque macrophages are both derived from circulating monocytes
that bind to activated endothelial cells and enter the intimal layer
as well as from local proliferating plaque macrophages [3]. The
mechanism that explains the persistent non-resolving inﬂamma-
tion within atherosclerotic plaques remains to be elucidated.
We recently proposed that trained immunity contributes to the
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persistent vascular inﬂammation that characterizes atherosclerotic
plaques [4]. Trained immunity denotes the process through which
innate immune cells can adopt a long-term pro-inﬂammatory
phenotype after brief exposure to certain pathogen- and danger-
associated molecular patterns, such as oxidized low density lipo-
protein (oxLDL) particles [5]. Brief in vitro exposure of human
monocytes to oxLDL induces a long-lasting pro-inﬂammatory
macrophage phenotype that is characterized by increased pro-
atherogenic cytokine and chemokine production and increased
foam cell formation. The key mechanisms underlying this pheno-
type are epigenetic reprogramming at the level of histone
methylation and a shift in the intracellular metabolism from
oxidative phosphorylation towards an increased aerobic glycolysis
(i.e. the Warburg effect) [6].
To test the hypothesis that trained immunity contributes to the
development of atherosclerosis, we now performed a ﬁrst proof-of-
concept study in patients with established atherosclerosis. We
aimed to investigate whether circulating monocytes of patients
with atherosclerosis have a pro-inﬂammatory phenotype, and
whether this is associated with epigenetic marks and change in
metabolism that are characteristic of trained immune cells. To
explore whether the role of trained immunity differs in the various
stages of atherosclerosis, we studied monocytes from patients with
symptomatic coronary atherosclerosis and subjects with asymp-
tomatic carotid atherosclerosis.
2. Materials and methods
Expanded Materials and methods are available in the
Supplementary materials.
2.1. Study participants
Patients with symptomatic coronary atherosclerosis were
selected from patients who had been referred to the cardiac
emergency ward of the Canisius Wilhelmina Hospital in Nijmegen,
from October 2013 to March 2014, because of chest pain, and who
were evaluated with coronary computed tomography angiography
(CCTA). We selected twenty patients with a total plaque score
(TPS) > 4 (patients) and twenty control patients with a TPS ¼ 0
(controls). Patients and controls were matched for age, gender and
body mass index (BMI). Exclusion criteria were an acute coronary
syndrome (at present or in the past), presence of a coronary stent,
bypass surgery in the past, heart failure, liver or renal failure, as
well as the use of anti-inﬂammatory medication other than statins,
and thrombocyte aggregation inhibitors. Additional exclusion
criteria were diabetes, rheumatoid arthritis, or other autoimmune
diseases and signs/symptoms of acute infection.
Patients with asymptomatic carotid atherosclerosis were
selected using carotid ultrasound from the participants of the
population-based IN CONTROL study, from October 2013 to July
2015. A total of 39 asymptomatic subjects were included. Exclusion
criteria for this study were a recent cardiovascular event, history of
bariatric surgery or bowel resection, inﬂammatory bowel disease,
renal dysfunction, increased bleeding tendency, use of oral subcu-
taneous anti-coagulant therapy, and use of thrombocyte aggrega-
tion inhibitors other than acetylsalicylic acid.
All laboratory analyses were performed blinded for group allo-
cation. The study protocol was approved by the Institutional Re-
view Board Arnhem/Nijmegen, The Netherlands, and prospectively
registered at Clinicaltrials.gov (number NCT02393768).
2.2. Evaluation of atherosclerotic burden
Atherosclerotic burden was assessed as described in the
Supplementary materials.
2.3. Blood sampling, isolation and stimulation of monocytes
EDTA plasma was obtained by venous blood sampling and was
stored using standardized protocols. Plasma total cholesterol, HDL-
c and LDL-c levels were analyzed using commercially available
enzymatic methods. PAXgene tubes (Preanalytix, GmbH,
Switzerland) were incubated for at least 2 h at room temperature
before storage at 20 C until RNA isolation.
Human peripheral blood mononuclear cells (PBMCs) were iso-
lated from EDTA blood using Ficoll-Paque density gradient centri-
fugation (GE Healthcare, UK). Monocytes were isolated bymagnetic
activated cell sorting (MACS) using CD14-coated MicroBeads ac-
cording to manufacturer's instructions (MACS, Miltenyi Biotec,
Leiden, The Netherlands). Monocytes were diluted to 1  106/ml in
RPMI 1640 Dutch-modiﬁed culture medium (Life Technologies/
Invitrogen, Breda, The Netherlands) supplemented with 10 mM
glutamine (Invitrogen), 10 mg/mL gentamicin (Centraform), 10 mM
pyruvate (Invitrogen). A total of 5 105monocytes were seeded per
well on ﬂat-bottom 96-well plates (Corning, New York, USA) and
stimulated for 24 h with RPMI only as a negative control, 10 ng/ml
LPS (Sigma-Aldrich, St. Louis, MO; from E. coli serotype 055:B5,
further puriﬁed as described [7]) or 10 mg/ml Pam3Cys (EMC
microcollections, Tübingen, Germany; L2000). After 24 h, plates
were centrifuged and supernatants were stored at 20 C until
cytokine assessment.
2.4. Cytokine measurements
Cytokine production was determined in supernatants as
described in Supplementary materials.
2.5. RNA isolation from PAXgenes
Total RNA puriﬁcation was performed as described in
Supplementary materials.
2.6. Chromatin immunoprecipitation
For the assessment of histone methylation, chromatin immu-
noprecipitation (ChIP) was performed as described previously [8].
In short, monocytes were cross-linked in methanol free 1% form-
aldehyde (28908, Thermo Scientiﬁc), followed by sonication to
shear-DNA and immunoprecipitation using antibodies against
H3K4me3, H3K27me3 and H3K9me3 (Diagenode, Seraing,
Belgium). ChIPed DNA was processed further for qPCR analysis.
Primers used in the reaction are listed in Supplementary Table 2.
Samples were analyzed following a comparative Ct method,
myoglobinwas used as a negative control for H3K4me3, GAPDH for
H3K9me3 and EIF4A2 for H3K27me3, H2B was used as a positive
control for H3K4me3, ZNF UTR for H3K9me3 and MYT1 for
H3K27me3 according to the manufacturer's instructions.
2.7. Statistics
Data are presented as mean (standard deviation) for continuous
variables and as number (percentage) for categorical variables. To
examine the difference in clinical characteristics between the
different patient groups, we performed unpaired student t-tests or
Mann-Whitney U tests for normal and non-normal distributed
variables, respectively. Ex vivo monocyte experiments were
analyzed using theMann-Whitney U test. In vitro experiments were
analyzed using the Wilcoxon signed rank test. A two-sided p-value
below 0.05 was considered statistically signiﬁcant. All data were
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analyzed using Prism version 5.0 (GraphPad software, La Jolla,
California) or SPSS version 21.0 (SPSS Inc., Chicago, Illinois).
3. Results
3.1. Baseline characteristics
Baseline characteristics of patients with symptomatic and sub-
jects with asymptomatic atherosclerosis, and controls for both
groups without atherosclerosis are listed in Table 1. The average
total plaque score (TPS) derived from the Coronary Computed To-
mography Angiography (CCTA) was 6.3 in patients (A), indicating
severe coronary atherosclerosis, and 0 in controls (B), indicating no
coronary atherosclerosis (Table 1). Patients with symptomatic
coronary atherosclerosis (group A) and controls (group B) were
matched for age, gender and body mass index (BMI). There were no
signiﬁcant differences between group A and B in blood pressure,
total cholesterol, lipoprotein(a), LDL cholesterol, glucose or plasma
creatinine. High density lipoprotein (HDL) cholesterol was slightly
lower in patients with coronary artery disease (CAD) (1.45 mmol/L
vs. 1.26 mmol/L, p ¼ 0,04). Statin use was higher in patients than
controls (75% vs. 15%, p < 0,001).
Similarly, therewere no signiﬁcant differences between subjects
with (C) andwithout (D) asymptomatic carotid plaques, besides the
presence of plaques measured by carotid ultrasound.
3.2. Increased systemic inﬂammation in patients with symptomatic
atherosclerosis
We measured baseline circulating high-sensitive C-reactive
protein (hsCRP), cytokines and chemokines in patients with
symptomatic CAD and controls. Plasma samples of patients with
symptomatic CAD did not show signiﬁcantly higher concentrations
of IL-6 and TNFa (Fig. 1A), although this may be due to the lack of
power. There was no difference in MCP-1 concentration. hsCRP was
signiﬁcantly higher in patients compared to controls (p < 0.01).
Subjects with asymptomatic carotid atherosclerosis showed no
differences in pro-inﬂammatory cytokines and hsCRP plasma con-
centrations (Fig. 1B) compared to controls.
3.3. Increased cytokine and chemokine production by monocytes
from subjects with symptomatic, but not asymptomatic
atherosclerosis
After overnight stimulation with the Toll-like receptor (TLR) 4
ligand lipopolysaccharide (LPS), monocytes isolated from patients
with symptomatic CAD showed an increased production of
interleukin-6 (IL-6), tumor necrosis factor-a (TNFa), IL-1b, IL-8 and
monocyte chemoattracting protein-1 (MCP-1; Fig. 2A) compared to
controls. Similar results were observed upon stimulation with the
TLR2 ligand Pam3Cys (Supplementary Fig. 1). No differences were
observed in production of the anti-inﬂammatory cytokine IL-10,
since levels were below detection level (data not shown).
In contrast, monocytes from subjects with asymptomatic carotid
atherosclerosis did not show increased production of IL-6, TNFa, IL-
1b, IL-8 and MCP-1, upon TLR4 stimulation, compared to control
subjects without carotid atherosclerosis (Fig. 2B). Similar results
were obtained after stimulation of leukocytes by the TLR2 ligand
Pam3Cys (Supplementary Fig. 2).
3.4. Circulating cells of patients with symptomatic CAD have a pro-
inﬂammatory phenotype associated with metabolic reprogramming
3.4.1. Increased pro-inﬂammatory cytokine expression
To further characterize the pro-inﬂammatory phenotype in pa-
tients with symptomatic CAD, we measured baseline RNA expres-
sion of pro-inﬂammatory cytokines and other inﬂammatory genes.
Baseline expression of TNFa, IL-1b and IL-1RA was signiﬁcantly
higher in patients with symptomatic CAD compared to controls
(Fig. 3A and Supplementary Fig. 3B), expression ofMCP-1, IL-8, IL-6
as well as expression of HIF-1a, c-MYC and STAT3 showed no
difference.
3.4.2. Increased expression of glycolytic enzymes
We have recently reported that the persistent pro-inﬂammatory
phenotype of monocytes after induction of trained immunity by b-
glucan is critically dependent on epigenetic reprogramming and a
metabolic shift towards increased aerobic glycolysis [6]. We
measured mRNA expression of hexokinase 2 (HK2) and 6-
phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3),
Table 1
Baseline characteristics of the participants.
Characteristics (A) Symptomatic coronary atherosclerosis
(n ¼ 20)
(B) Controls
(n ¼ 20)
p value (C) Asymptomatic carotid atherosclerosis
(n ¼ 17)
(D) Controls
(n ¼ 22)
p value
Age, y 52 ± 11 53 ± 12 0.78 67 ± 6 66 ± 4 0.43
Gender, % male (n) 75 (15) 50 (10) 0.19 29 (5) 45 (10) 0.32
BMI (kg/m2) 28.6 ± 4.1 26.5 ± 3.5 0.08 29.6 ± 2.3 31.1 ± 4.7 0.24
SBP (mmHg) 145 ± 21 142 ± 17 0.63 130 ± 10 130 ± 14 0.95
DBP (mmHg) 80 ± 14 83 ± 11 0.54 79 ± 6 82 ± 9 0.22
Family history, % yes (n) 60 (12) 35 (7) 0.21 47 (8) 37 (8) 0.24
Smoking, % active (n) 20 (4) 20 (4) e 6 (1) 9 (2) 0.72
Smoking (pack years) 18 ± 12 22 ± 20 0.47 e e
Statin use, % yes (n) 75 (15) 15 (3) 0.00 0 (0) 0 (0) 1
TChol, mmol/L 5.1 ± 1.2 4.9 ± 1.7 0.92 6.2 ± 0.9 6.0 ± 1.07 0.55
LDLc, mmol/L 3.0 ± 1.0 2.9 ± 1.2 0.93 4.12 ± 0.8 4.0 ± 0.9 0.47
HDLc, mmol/L 1.3 ± 0.3 1.5 ± 0.6 0.04 1.4 ± 0.3 1.4 ± 0.2 0.70
Lp(a), mg/L 281.9 ± 341.6 266.1 ± 479.1 0.68 e e
Glucose, mmol/L 6.3 ± 1.8 5.8 ± 1.6 0.37 5.4 ± 0.8 5.3 ± 0.7 0.71
Creatinine mmol/L 86.7 ± 13.8 80.3 ± 16.5 0.19 82.2 ± 12.5 80.1 ± 17.2 0.67
% Monocytes 12.3 ± 3.5 13.5 ± 4.3 0.34 8.6 ± 1.3 8.9 ± 2.1 0.65
Total Plaque Score (TPS) 6.3 [4e12] 0 <0.0001 e e e
Plaque on carotid
ultrasound %(n)
e e - 100 (17) 0 (22) <0.0001
Data are presented as mean ± SD or n (%).
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TChol, total cholesterol; LDLc, low density lipoprotein cholesterol; HDLc, high density
lipoprotein cholesterol; Lp(a), lipoprotein (a).
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the two rate-limiting enzymes in the glycolysis pathway, as well as
the expression of other important metabolic enzymes in patients
with symptomatic CAD and control patients. Patients with symp-
tomatic CAD showed a higher baseline expression of HK2, PFKFB3,
pyruvate kinase 1 (PKM1), argininosuccinate lyase (ASL), malate
dehydrogenase 1 (MDH1), pyruvate dehydrogenase alpha 1
(PDHA1) and transaldolase 1 (TALDO1) (Fig. 3A and Supplementary
Fig. 3B). This is consistent with an upregulation of genes of the
glycolytic pathway, but also enzymes in the pentose-phosphate
pathway and Krebs cycle (Fig. 3B). Expression of HK2 and IL-1b
(R ¼ 0.41, p ¼ 0.01), PFKFB3 and TNFa (R ¼ 0.45, p ¼ 0.006) and
PFKFB3 and IL-1b (R ¼ 0.78, p < 0.001) are signiﬁcantly correlated,
corroborating an association between upregulated glycolysis and
an increased baseline inﬂammatory state (Supplementary Fig. 3A).
3.5. Increased cytokine production is associated with lower
repressive epigenetic marks in patients with symptomatic CAD
Trained immunity is mediated by epigenetic reprogramming at
the level of histone methylation [9]. Previously, we showed that
increased cytokine production after brief exposure to oxLDL or b-
glucanwas associated with an enrichment of the activating histone
mark H3K4me3, and training was prevented by nonselective in-
hibitors of methyltransferases [5,10]. Since patients with symp-
tomatic CAD have elevated pro-inﬂammatory cytokine production
on baseline, as well as increased pro-inﬂammatory cytokine pro-
duction upon ex vivo stimulation, we hypothesized that this is due
to epigenetic reprogramming of the monocyte population. We
assessed H3K4me3 levels on the promoters of IL-6, IL-1b and TNFa,
since thesewere signiﬁcantly upregulated upon ex vivo stimulation.
Surprisingly, and in contrast to what we observed in our in vitro
experiments with b-glucan and oxLDL-induced training [5], the
promoters of these pro-inﬂammatory genes had lower H3K4me3 in
patients with symptomatic CAD than controls (Fig. 4A). Since TNFa
showed the most signiﬁcant increase in both plasma levels, base-
line RNA expression as well as ex vivo production in patients vs.
controls, we investigated this cytokine in more detail. Using six
primers covering most part of the promoter (Supplementary
Fig. 4A), we conﬁrmed consistent downregulation of H3K4me3
throughout the promoter (Fig. 4B).
The overall activation state of the chromatin, however, is
dictated not only by the activating mark H3K4me3, but also by
alternative activating marks and repressive marks. Two important
repressive histone marks are trimethylation of H3K9 and trime-
thylation of H3K27 [11]. H3K27me3, in particular, has been asso-
ciated with control of gene expression upon ex vivo LPS stimulation
[12,13]. Using our in vitro model of oxLDL training, we observed
long-term lower repressive marks on the promoter regions of pro-
inﬂammatory genes. Both H3K9me3 as well as H3K27me3 in vitro
are lower in trained than untrained monocytes for IL-6 and TNFa
(Supplementary Fig. 4B). Following these observations, we were
interested in the repressive marks in our patients. For H3K9me3, no
signiﬁcant differences were observed on the TNFa promoter region
(Fig. 4C). With regard to H3K27me3, the TNFa promoter showed a
lower occupancy throughout the whole promoter (p < 0.0001,
Fig. 4D). Interestingly, levels of H3K27me3 were correlated with
levels of H3K4me3 on TNFa promoter (R ¼ 0.37, p ¼ 0.03, Fig. 4E)
and negatively correlated with the expression of TNFa itself
(R ¼ 0.41, p ¼ 0.02, Fig. 4E). Expression of EZH2, the only meth-
yltransferase known to induce H3K27me3 was not different be-
tween patients and controls (Fig. 4D). H3K9me3 and H3K27me3
showed no differences for IL-6 and IL-1b (Supplementary Fig. 4C).
4. Discussion
The results of this study add additional evidence in favor of the
hypothesis that trained innate immunity contributes to the process
of atherosclerosis [4]. We demonstrated that circulating monocytes
of patients with established atherosclerosis have a pro-
inﬂammatory phenotype, associated with epigenetic remodeling
at the level of histone methylation and increased expression of rate
limiting enzymes of the glycolysis pathway and the pentose
phosphate pathway. Interestingly, this pro-inﬂammatory pheno-
type was present only in patients with severe symptomatic coro-
nary atherosclerosis, and not in patients with mild asymptomatic
carotid atherosclerosis.
Fig. 1. Inﬂammatory markers in plasma. (A) IL-6, TNFa, MCP-1 and hsCRP were measured in EDTA plasma from patients with symptomatic CAD vs. matched controls. Baseline
inﬂammation in patients with symptomatic CAD was increased compared to controls. (B) IL-6 and hsCRP were measured in plasma from patients with asymptomatic carotid
atherosclerosis vs. matched controls. Asymptomatic carotid atherosclerosis subjects showed no increased baseline inﬂammation compared to controls.
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The underlying molecular basis of trained immunity is only
partially deciphered and comprises changes in chromatin organi-
zation and intracellular metabolism. In human monocytes trained
with b-glucan, a shift from oxidative phosphorylation towards
aerobic glycolysis through the AKT-mTOR-HIF-1a pathway was
observed, accompanied by changes in histone marks such as
H3K4me1, H3K4me3 and H3K27Ac. Both pathways are non-
redundant, since pharmacological inhibitors of glycolysis, such as
2-deoxy-D-glucose and inhibitors of the mTOR pathway, such as
metformin, as well as non-speciﬁc inhibitors of histone methyl-
transferases, prevented b-glucan-induced trained immunity [6,10].
Here we show that in patients with symptomatic CAD, mono-
cytes display an increased pro-inﬂammatory cytokine response
upon ex vivo TLR4/2 stimulation. Previously, ex vivo inﬂammatory
responses in patients with and without atherosclerosis were
studied mainly in whole blood or peripheral blood mononuclear
cells (PBMCs) [14e16]. In addition, baseline expression of cytokines,
baseline expression of the two rate-limiting glycolysis genes, as
well as the expression of several other enzymes in glycolysis,
pentose phosphate pathway and Krebs cycle were increased in
whole blood. In this study, the pro-inﬂammatory phenotype was
also associated with changes in the epigenetic landscape in the
monocytes. First, we studied the level of H3K4me3, a long-term
activating histone mark. In contrast to our in vitro observations,
however, H3K4me3 occupancy on TNFa promoter was lower in
patients with CAD. The accessibility of the chromatin is determined
by activating epigenetic marks as well as repressive epigenetic
marks. The repressive mark H3K27me3 importantly contributes to
the LPS-induced pro-inﬂammatory cytokine production [12]. Pre-
viously, Wierda et al. used immunohistochemistry to show a
Fig. 2. Ex vivo stimulation of monocytes. (A) Monocytes from patients with symptomatic CAD have a pro-inﬂammatory phenotype upon ex vivo stimulation of TLR4 compared to
matched controls. Monocytes from patients and controls were stimulated with TLR4 ligand LPS for 24 h and IL-6, TNFa, IL-1b, IL-8 and MCP-1 were measured in the supernatant
after 24 h of incubation at 37 C, 5% CO2 (n ¼ 20 vs. 20, *p < 0.05, **p < 0.01). (B) Monocytes from patients with asymptomatic carotid atherosclerosis do not show an increased pro-
inﬂammatory phenotype upon ex vivo stimulation of TLR4. Monocytes from subjects with carotid atherosclerosis and controls were stimulated with TLR4 ligand LPS for 24 h and IL-
6, TNFa, IL-1b, IL-8 and MCP-1 were measured in the supernatant after 24 h of incubation at 37 C, 5% CO2.
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reduction of global levels of H3K27me3 modiﬁcation in vessels
with advanced plaques, which was not accompanied by alterations
in global levels of the corresponding histone methyltransferase
EZH2 [17], corresponding to our current ﬁndings. Greissel et al.
showed a signiﬁcant reduction of repressive marks H3K9me2 and
H3K27me2 with increasing plaque severity, in plaque macrophages
[18]. Although measured in plaque macrophages and not in circu-
lating cells, these studies indicate that repressive marks are
strongly associated with the severity of atherosclerotic disease. In
our study, we also determined H3K9me3 and H3K27me3 on the
TNFa promoter. Although H3K9me3 was not signiﬁcantly different
between patients with and without atherosclerosis, H3K27me3
was much lower and correlated with cytokine RNA expression
levels. Recently, Schmidt et al. studied the transcriptional regulator
network of human inﬂammatory macrophages by histone marks.
They showed that when promoter regions only have H3K4me3
marks, they are in an open chromatin state.When promoter regions
are additionally trimethylated on H3K27me3, the promoter region
is ‘poised’ and transcription is prevented [19]. Furthermore, Krui-
denier et al. showed that H3K27 demethylation is a critical deter-
minant for LPS induced TNFa production, and higher baseline levels
of H3K27me3 can result in lower TNFa production [12].
Baseline RNA expression analysis showed increased expression
of the rate-limiting enzymes of the glycolytic pathway as well as
Fig. 3. Increased baseline inﬂammation and glycolysis in patients with symptomatic CAD. (A) Baseline RNA expression of cytokines and metabolic rate-limiting enzymes is
signiﬁcantly increased in patients with symptomatic CAD compared to controls (high expression ¼ red, low expression ¼ blue) (n ¼ 17 vs. 18). (B) Schematic overview of metabolic
pathways and signiﬁcantly upregulated genes in patients with CAD, highlighted in green.
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other important rate-limiting metabolic enzymes in patients with
severe atherosclerosis. Previously, we have shown that trained
immunity depends on a metabolic shift, resulting in increased
glycolysis [6,10]. An increase in gene expression of the two rate-
limiting glycolytic genes is compatible with this metabolic shift
that characterizes trained immunity [10]. The upregulation of other
rate-limiting metabolic enzymes involved in the pentose phos-
phate pathway and Krebs cycle indicates a more general activation
of intracellular metabolism, as shown in Fig. 4B. Recently, Tawakol
et al. showed that in plaque macrophages there is a relationship
between PFKFB3 expression and pro-inﬂammatory activation, via
hypoxia-induced upregulation of macrophage glycolysis. The
authors showed a linear relationship between macrophage ener-
getics on the one hand and inﬂammatory activation on the other
hand, regulated via PFKFB3 expression [20]. Furthermore, Shirai
et al. showed that circulating monocytes and monocyte-derived
macrophages from patients with established atherosclerosis have
increased inﬂammation and glycolysis [21]. This study, however,
differs markedly from our study, since these patients already suf-
fered from an acute myocardial infarction, which in itself is a well-
known trigger of innate immune activation [22]. In our study, all
subjects with coronary atherosclerosis were free from previous
cardiovascular events. Here we show, for the ﬁrst time, that base-
line gene expression of glycolysis and intracellular metabolism
Fig. 4. Patients with symptomatic CAD have a different epigenetic landscape than healthy controls. (A) Chromatin immunoprecipitation of H3K4me3 in monocytes from
patients with symptomatic CAD and controls was performed. Levels of H3K4me3 were measured on the promoters of tnfa, il-6 and il-1b and were lower in patients compared to
controls. (B) The tnfa promoter was studied in more detail and showed an overall lower H3K4me3 throughout the promoter region (C) ChIP of repressive mark H3K9me3 showed no
signiﬁcant difference in H3K9me3 on the promoter of tnfa in patients compared to controls. (D) ChIP of repressive mark H3K27me3 showed a signiﬁcantly lower H3K27me3
throughout the tnfa promoter in patients compared to controls. The expression of the methyltransferase EZH2 for H3K27me3 showed no difference. (E) The level of H3K27me3 was
negatively correlated with baseline RNA expression of tnfa. Levels of H3K4me3 and H3K27me3 are correlated as well (n ¼ 20 vs. 20, *p < 0.05, **p < 0.01, ***p < 0.001).
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genes in circulating cells is also increased in event-free patients
with established atherosclerosis, which is also associated with
changes in the epigenetic landscape.
We propose that the pro-inﬂammatory phenotype of circulating
monocytes in patients with severe coronary atherosclerosis reﬂects
a trained immune phenotype, but we can only speculate about the
stimulus that has instigated this immunological program. We have
previously shown that several PAMPs and DAMPs can induce
trained immunity, including Bacillus Calmette-Guerin, Candida
albicans, b-glucan, and pro-atherogenic stimuli such as modiﬁed
LDL and Lp(a) [5,8,9,23]. Our patients and controls did not show any
differences in total cholesterol levels, LDL cholesterol or Lp(a), but
the majority of the patients were being treated with statins. It is
probable that before the initiation of statin treatment, LDL was
higher in patients with CAD. Furthermore, the effects of statins on
epigenetic modiﬁcations are still unknown. HDL cholesterol was
lower in patients, but we do not yet know the effects of HDL
cholesterol on trained immunity. Interestingly, the trained immune
phenotype of circulation monocytes was only present in patients
with severe symptomatic coronary atherosclerosis, and not in pa-
tients with asymptomatic carotid atherosclerosis, which was
diagnosed by screening of healthy subjects. A potential explanation
for this ﬁnding is that trained immunity contributes to the pro-
gression of complex atherosclerotic plaques and not to the initial
formation of early lesions, which are observed in the majority of
subjects. This ﬁnding is consistent with previous ﬁndings in pa-
tients with elevated levels of lipoprotein(a), which can also induce
trained immunity in vitro [23]. Interestingly, most studies report
that elevated lipoprotein (a) is not associated with early athero-
sclerotic lesions (e.g. carotid IMT) whereas elevated lipoprotein(a)
is consistently associated with cardiovascular events, which mostly
result from vulnerable atherosclerotic plaques [24e26]. Obviously,
this ﬁnding requires conﬁrmation in a larger cohort of patients.
Our study has several potential limitations. First of all, our re-
sults only indicate an association between atherosclerosis and
trained immunity, and do not provide proof of causality. In theory,
effects on the immune system could be caused by the atheroscle-
rosis itself. Intervention studies in animal models of atherosclerosis
will be required to provide ﬁnal proof that trained immunity con-
tributes to the development/progression of atherosclerosis. Sec-
ondly, the majority of patients with CAD used statins, in contrast to
the control group. However, since statins are known to have potent
anti-inﬂammatory effects [27], it is very unlikely that they have
contributed to the pro-inﬂammatory monocyte phenotype,
although they may have partially masked its full effects. Thirdly, it
is important to realize that RNA expression was studied in whole
blood using PAXgene tubes, to prevent changes in the RNA
expression levels by the isolation of monocytes. However, it is likely
that differences in RNA expression that we observed between pa-
tients with and without atherosclerosis are relevant for the
monocyte fraction: ﬁrst, we measured expression of various cyto-
kines that are predominantly derived from monocytes, including
TNF, IL1b, and IL6. Secondly, there is a strong correlation between
the expression of enzymes of the glycolytic pathway (HK2/PFKFB3)
and these cytokines, suggesting that this increased glycolysis is
relevant for monocytes. Finally, in a previous study in patients with
atherosclerosis, an increased expression of glycolytic enzymes was
also observed in isolated monocytes after differentiation into M1
macrophages, compared to monocytes from patients without
atherosclerosis [21].
Finally, with regard to the epigenetic reprogramming, we have
only focused on a few epigenetic marks on the promoters of the
various cytokines. We studied the ChIPed promoters of genes that
were upregulated in protein and RNA expression and searched for
association, whereas a more unbiased approach (e.g. genome wide
ChIP seq) could reveal new pathways and models for explaining
differences.
Here we show that monocytes of patients with symptomatic
CAD but not patients with asymptomatic carotid atherosclerosis
have a pro-inﬂammatory phenotype, which is associated with
metabolic reprogramming on the level of RNA expression towards
increased glycolysis, and with epigenetic remodeling of pro-
inﬂammatory genes. These ﬁndings suggest that trained immu-
nity could play a role in the progression of mild and asymptomatic
atherosclerotic plaques towards symptomatic disease.
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